Selected sexually transmitted diseases and their relationship to HIV

Clinics in Dermatology

Volumn 22, Issue 6, 2004, Pages 499-508

  Wu, Jashin J ^a   Huang, David B ^b,c,d   Pang, Katie R ^e   Tyring, Stephen K ^f,g  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^e WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF TEXAS   (United States)

^g CENTER FOR CLINICAL STUDIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AZITHROMYCIN; CEFTRIAXONE; CIPROFLOXACIN; COTRIMOXAZOLE; DOXYCYCLINE; ERYTHROMYCIN; FAMCICLOVIR; FLEROXACIN; GENTAMICIN; VALACICLOVIR;

CALYMMATOBACTERIUM GRANULOMATIS; CHLAMYDIA TRACHOMATIS; CLINICAL FEATURE; DIAGNOSTIC PROCEDURE; DRUG CONTRAINDICATION; DRUG EFFICACY; EPIDEMIOLOGICAL DATA; GENITAL HERPES; GRANULOMA INGUINALE; HAEMOPHILUS DUCREYI; HERPES SIMPLEX; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOGRANULOMA VENEREUM; MORBIDITY; MORTALITY; PRIORITY JOURNAL; REVIEW; SEXUALLY TRANSMITTED DISEASE; SOCIOECONOMICS; ULCUS MOLLE;

EID: 10944242373     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clindermatol.2004.07.008     Document Type: Article

References (120)

1. US Department of Health and Human Services, Public Health Service. Tracking the hidden epidemics: trends in STDs in the United States 2000. 2000;Centers for Disease Control, Atlanta. 1-36
2. Schulte J.M., Martich F.A., Schmid G.P. Chancroid in the United States 1981-1990: evidence for underreporting of cases. MMWR. 41:1992;57-61
3. Bogaerts J., Ricart C.A., Van Dyck E., et al. The etiology of genital ulceration in Rwanda. Sex Transm Dis. 16:1989;123-126
4. Boyd A.S. Clinical efficacy of antimicrobial therapy in Haemophilus ducreyi infections. Arch Dermatol. 25:1989;1399-1405
5. Brown T.J., Yen-Moore A., Tyring S.K. An overview of sexually transmitted diseases Part I. J Am Acad Dermatol. 41:1999;511-532
6. Goens J.L., Schwartz R.A., de Wolf K. Mucocutaneous manifestations of chancroid, lymphogranuloma venereum and granuloma inguinale. Am Fam Physician. 49:1994;415-425
7. Buntin D.M., Rosen T., Lesher J.L., et al. Sexually transmitted diseases: bacterial infections. J Am Acad Dermatol. 25:1991;287-299
8. Rosen T., Dhir A. Chancroid, granuloma inguinale, and lymphogranuloma venereum. Arndt K.A. Cutaneous medicine and surgery, an integrated program in dermatology. 1996;973-982 WB Saunders, Philadelphia
9. Tyndall M.W., Plourde P.J., Agoki E., et al. Fleroxacin in the treatment of chancroid: an open study in men seropositive or seronegative for the human immunodeficiency virus type 1. Am J Med. 94:(Suppl 3A):1993;85S-88S
10. Manget-Velasco C.S., Borbujo-Martinez J., Manzanode Arostegui J.A., et al. Soft chancroid: 4 clinical cases. Atencion Primaria. 12:1993;667-670
11. Kimani J., Bwayo J.J., Anzala A.O., et al. Low dose erythromycin regimen for the treatment of chancroid. East Afr Med J. 72:1995;645-648
12. King R., Choudhri S.H., Nasio J., et al. Clinical and in situ cellular responses to Haemophilus ducreyi in the presence or absence of HIV infection. Int J STD AIDS. 9:1998;531-536
13. Humphreys T.L., Schnizlein-Bick C.T., Katz B.P., et al. Evolution of the cutaneous immune response to experimental Haemophilus ducreyi infection and its relevance to HIV-1 acquisition. J Immunol. 169:2002;6316-6323
14. Chapel T.A., Brown W.J., Jeffries C., et al. How reliable is the morphological diagnosis of penile ulcerations? Sex Transm Dis. 4:1977;150-152
15. Werman B.S., Herskowitz L.J., Olansky S., et al. A clinical variant of chancroid resembling granuloma inguinale. Arch Dermatol. 119:1983;890-894
16. Sturm A.W., Stolting G.J., Cormane R.H., et al. Clinical and microbiological evaluation of 46 episodes of genital ulceration. Genitourin Med. 63:1987;98-101
17. Schmid G.P. Approach to the patient with genital ulcer disease. Med Clin North Am. 74:1990;1559-1572
18. Strakosch E.A., Kendall H.W., Craig R.M., et al. Clinical and laboratory investigation of 370 cases of chancroid. J Invest Dermatol. 6:1945;95-107
19. Schmid G.P., Faur Y.C., Valu J.A., et al. Enhanced recovery of Haemophilus ducreyi from clinical specimens by incubation at 33 versus 355C. J Clin Microbiol. 33:1995;3257-3259
20. Karim Q.N., Finn G.Y., Easmon C.S.F., et al. Rapid detection of Haemophilus ducreyi in clinical and experimental infections using monoclonal antibody. Genitourin Med. 65:1989;361-365
21. Schalla W.O., Sanders L.L., Schmid G.P., et al. Use of dot-immunobinding and immunofluorescence assays to investigate clinically suspected cases of chancroid. J Infect Dis. 153:1986;879-887
22. Joseph A.K., Rosen T. Laboratory techniques used in the diagnosis of chancroid, granuloma inguinale, and lymphogranuloma venereum. Dermatol Clin. 12:1994;1-8
23. Magro C.M., Crowson A.N., Alfa M., et al. A morphological study of penile chancroid lesions in human immunodeficiency virus (HIV)-positive and -negative African men with a hypothesis concerning the role of chancroid in HIV transmission. Hum Pathol. 27:1996;1066-1070
24. Centers for Disease Control and Prevention. 2002 Guidelines for treatment of sexually transmitted diseases. MMWR. 51:2002;1-80
25. Lewis D.A. Chancroid: clinical manifestations, diagnosis, and management. Sex Transm Infect. 79:2003;68-71
26. Czelusta A., Yen-Moore A., Van der Straten M., et al. An overview of sexually transmitted diseases Part III. Sexually transmitted diseases in HIV-infected patients. J Am Acad Dermatol. 43:2000;409-432
27. Tyndall M., Agoki E., Plummer F.A., et al. Single dose azithromycin for the treatment of chancroid: a randomized comparison with erythromycin. Sex Transm Dis. 21:1994;231-234
28. Tyndall M., Malisa M., Plummer F.A., et al. Ceftriaxone no longer predictably cures chancroid in Kenya. J Infect Dis. 167:1993;469-471
29. MacDonald K.S., Cameron D.W., D'Costa L.J., et al. Evaluation of fleroxacin (RO 23-6240) as single-oral-dose therapy of culture-proven chancroid in Nairobi, Kenya. Antimicrob Agents Chemother. 33:1989;612-614
30. Plourde P.J., D'Costa L.J., Agoki E., et al. A randomized, double-blind study of the efficacy of fleroxacin versus trimethoprim-sulfamethoxazole in men with culture-proven chancroid. J Infect Dis. 165:1992;949-952
31. Kinghorn GR. Genital herpes: natural history and treatment of acute episodes. J Med Virol 1993; Suppl 1:33-8
32. Fleming D.T., McQuillan G.M., Johnson R.E., et al. Herpes simplex virus type 2 in the United States, 1976 to 1994. N Engl J Med. 337:1997;1105-1111
33. Arvin A.M., Prober C.G. Herpes simplex virus type 2: a persistent problem. N Engl J Med. 337:1997;1158-1159
34. Pereira F.A. Herpes simplex: evolving concepts. J Am Acad Dermatol. 35:1996;503-520
35. Langenberg A., Benedetti J., Jenkins J., et al. Development of clinically recognizable genital lesions among women previously identified as having "asymptomatic" herpes simplex virus type 2 infection. Ann Intern Med. 110:1989;882-887
36. Larkin J.A., Minerva K., Holt D., et al. Women and HIV: when to test? AIDS Read. 9:1999;175-176., 179-80, 183
37. Mbopi-Keou F.X., Robinson N.J., Mayaud P., et al. Herpes simplex virus type 2 and heterosexual spread of human immunodeficiency virus infection in developing countries: hypotheses and research priorities. Clin Microbiol Infect. 9:2003;161-171
38. Boulos R., Ruff A.J., Nahmias A., et al. Herpes simplex virus type 2 infection, syphilis, and hepatitis B virus infection in Haitian women with human immunodeficiency virus type 1 and human T lymphotropic virus type 1 infections. J Infect Dis. 166:1992;418-420
39. Holmberg S.D., Stewart J.A., Gerber A.R., et al. Prior herpes simplex virus type 2 infection as a risk factor for HIV infection. JAMA. 259:1988;1048-1050
40. Hook E.W., Cannon R.O., Nahmias A.J., et al. Herpes simplex virus as a risk factor for human immunodeficiency virus infection in heterosexuals. J Infect Dis. 165:1992;251-255
41. Stamm W.E., Handsfield H.H., Rompalo A.M., et al. The association between genital ulcer disease and acquisition of HIV infection in homosexual men. JAMA. 260:1988;1429-1433
42. Wald A., Link K. Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis. J Infect Dis. 185:2002;45-52
43. Golden M.P., Kim S., Hammer S.M., et al. Activation of human immunodeficiency virus by herpes simplex virus. J Infect Dis. 166:1992;494-499
44. Heng M.C., Heng S.Y., Allen S.G. Co-infection and synergy of human immunodeficiency virus-1 and herpes simplex virus-1. Lancet. 343:1994;255-258
45. Mole L., Ripich S., Margolis D., et al. The impact of active herpes simplex virus infection on human immunodeficiency virus load. J Infect Dis. 176:1997;. 766-60
46. Mosca J.D., Bednarik D.P., Raj N.B., et al. Herpes simplex virus type-1 can reactivate transcription of latent human immunodeficiency virus. Nature. 325:1987;67-70
47. Siegal F.P., Lopez C., Hammer G.S., et al. Severe acquired immunodeficiency in male homosexuals, manifested by chronic perianal ulcerative herpes simplex lesions. N Engl J Med. 305:1981;1439-1444
48. Quinnan G., Masur H., Rook A.H., et al. Herpesvirus infections in the acquired immunodeficiency syndrome. JAMA. 252:1984;72-77
49. Maier J., Bergman A., Ross M. Acquired immunodeficiency syndrome manifested by chronic primary genital herpes. Am J Obstet Gynecol. 155:1986;756-758
50. Skinhoj P. Herpesvirus infections in the immunocompromised patient. Scand J Infect Dis. 47:(Suppl):1985;121-127
51. Bagdades E., Pillay D., Squire S., et al. Relationship between herpes simplex virus ulceration and CD4+ cell counts in patients with HIV infection. AIDS. 6:1992;1317-1320
52. Augenbraun M., Feldman J., Chirgwin K., et al. Increased genital shedding of herpes simplex virus type 2 in HIV-seropositive women. Ann Intern Med. 123:1995;845-847
53. Stover C.T., Smith D.K., Schmid D.S., et al. HIV epidemiology research study group Prevalence of and risk gactors for viral infections among human immunodeficiency virus (HIV)-infected and high-risk HIV-uninfected women. J Infect Dis. 187:2003;1388-1396
54. Centers for Disease Control. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR. 41:1992;1-19
55. Tayal S.C., Pattman R.S., McLelland J., et al. An indolent penile herpetic ulcer in a patient with previously undiagnosed human immunodeficiency virus infection. Br J Dermatol. 138:1998;334-336
56. Horner P., Harris J. A herpes simplex skin ulcer in a patient with AIDS: an unusual presentation. Int J STD AIDS. 1:1990;288-289
57. Ashley R., Cent A., Maggs V., et al. Inability of enzyme immunoassays to discriminate between infections with herpes simplex virus types 1 and 2. Ann Intern Med. 115:1991;520-526
58. Ashley R. Laboratory techniques in the diagnosis of herpes simplex infection. Genitourin Med. 64:1993;174-183
59. Corey L., Homes K.K. Genital herpes simplex virus infections: current concepts in diagnosis, therapy, and prevention. Ann Intern Med. 78:1983;973-983
60. Lafferty W.E., Coombs R.W., Benedetti J., et al. Recurrences after oral and genital herpes simplex virus infection: influence of site of infection and viral type. N Engl J Med. 316:1987;1444-1449
61. Wald A., Corey L., Cone R., et al. Frequent genital herpes simplex virus shedding in immunocompetent women: effect of acyclovir treatment. J Clin Invest. 99:1997;1092-1097
62. Dignani M.C., Mykietiuk A., Michelet M., et al. Valacyclovir prophylaxis for the prevention of herpes simplex virus reactivation in recipients of progenitor cells transplantation. Bone Marrow Transplant. 29:2002;263-267
63. Schacker T., Hu H., Koelle D.M., et al. Famciclovir for the suppression of symptomatic and asymptomatic herpes simplex virus reactivation in HIV-infected persons: a double-blind, placebo controlled trial. Ann Intern Med. 128:1998;21-28
64. Wu JJ, Brentjens MH, Torres G, et al. Valacyclovir in the treatment of herpes simplex, herpes zoster and other viral infections. J Cutan Med Surg. In press
65. Douglas J.M., Critchlow C., Benedetti J., et al. A double-blind study of oral acyclovir for suppression of recurrences of genital herpes simplex virus infection. N Engl J Med. 310:1984;1551-1556
66. Strauss S.E., Takiff H.E., Seidlin M., et al. Suppression of frequently recurring genital herpes: a placebo-controlled double-blind trial of oral acyclovir. N Engl J Med. 310:1984;1545-1550
67. Augenbraun M.H., McCormack W.M. Sexually transmitted diseases in HIV-infected persons. Infect Dis Clin North Am. 8:1994;439-448
68. Lawrence A, Bell A. Valacyclovir for prevention of recurrent herpes virus infection in HIV-infected individuals: a double blind controlled trial. Presented at: 8th European Congress of Clinical Microbiology and Infectious Diseases; May 25-28, 1997; Lausanne, Switzerland
69. Ioannidis J., Collier A., Cooper D., et al. Clinical efficacy of high-dose acyclovir in patients with human immunodeficiency virus infection: a meta-analysis of randomized individual patient data. J Infect Dis. 178:1998;349-359
70. Locke L, Young C, Saltzman R. Famciclovir safety experience in long-term treatment and in immunocompromised patients. Presented at: 8th International Congress on Infectious Diseases; May 15-18, 1998; Boston, MA
71. Burnside A, Preston R, Crann R, et al. Famciclovir for suppression of recurrent genital herpes in HIV-infected patients. Presented at: 36th Annual Meeting of the Infectious Disease Society of America; Nov 12-15, 1998; Denver, CO
72. Conant M.A., Schacker T.W., Murphy R.L., et al. Valaciclovir versus acyclovir for herpes simplex virus infection in HIV-infected individuals: two randomized trials. Int J STD AIDS. 13:2002;12-21
73. Rosen T., Tschen J.A., Ramsdell W., et al. Granuloma inguinale. J Am Acad Dermatol. 11:1984;433-437
74. O'Farrell N. Donovanosis. Sex Transm Infect. 78:2002;452-457
75. Richens J. The diagnosis and treatment of donovanosis (granuloma inguinale). Genitourin Med. 67:1991;441-452
76. Kharsany A.B.M., Hoosen A.A., Kiepiela P., et al. Growth and cultural characteristics of Calymmatobacterium granulomatis: the aetiological agent of granuloma inguinale (Donovanosis). J Med Microbiol. 46:1997;579-585
77. Hart G. Donovanosis. Clin Infect Dis. 25:1997;24-32
78. Lal S., Nicholas C. Epidemiological and clinical features in 165 cases of granuloma inguinale. Br J Vener Dis. 46:1970;461-463
79. Mitchell K.M., Roberts A.N., Williams V.M., et al. Donovanosis in Western Australia. Genitourin Med. 62:1986;191-195
80. Packer H., Goldberg J. Studies of the antigenic relationship of D. granulomatis to members of the tribe Escherichae. Am J Syphilis Gonorrhea Vener Dis. 34:1950;342-350
81. Serma J.S. Granuloma venereum: a problem in Guntur. Indian J Dermatol Venereol Leprol. 5:1969;45-52
82. Ramachander M., Jayalakshmi S., Pankaja P. A study of donovanosis in Guntur. Indian J Dermatol Venereol Leprol. 3:1967;237-241
83. Vimla Bai K., Sulibhari D.G., Shyam Sunder P. A study of donovanosis. Indian J Dermatol Venereol Leprol. 35:1969;45-52
84. Sehgal V.N., Sharma N.L., Bhargava N.C., et al. Primary extragenital disseminated cutaneous donovanosis. Br J Dermatol. 101:1979;353-356
85. Packer H., Turner H.B., Dulaney A.D. Granuloma inguinale of the vagina and cervix uteri with bone metastases. JAMA. 136:1961;327-329
86. Brigden M., Guard R. Extragenital granuloma inguinale in North Queensland. Med J Aust. 2:1980;565-567
87. Maddocks I., Anders E.M., Dennis E. Donovanosis in Papua New Guinea. Br J Vener Dis. 52:1976;190-196
88. Brain P. Granuloma inguinale with extensive oral involvement. S Afr Med J. 25:1951;581-582
89. Jennison D.B., Helwig E.B., Milstone J.H. Granuloma inguinale involving buttock and lymph node. Arch Dermatol Syphilol. 55:1947;342-354
90. Jamkhedkar P.P., Hira S.K., Shroff H.J., et al. Clinico-epidemiologic features of granuloma inguinale in the era of acquired immune deficiency syndrome. Sex Transm Dis. 25:1998;196-200
91. O' Farrell N. Donovanosis: an update. Int J STD AIDS. 12:2001;423-427
92. Hacker P., Fisher B.K., Dekoven J., et al. Granuloma inguinale: three cases diagnosed in Toronto, Canada. Int J Dermatol. 31:1992;696-699
93. Packer H., Dulaney A.D. Diagnostic tests in granuloma inguinale. Am J Syphilis. 33:1949;68-75
94. Marmell M., Santora E. Donovanosis-granuloma inguinale: incidence, nomenclature, and diagnosis. Am J Syphilis. 34:1950;83-90
95. Kharsany A.B.M., Hoosen A.A., Kiepiola P., et al. Culture of Calymmatobacterium granulomatis. [letter] Clin Infect Dis. 22:1996;391
96. Carter J., Hutton S., Sriprakash K.S., et al. Culture of the causative organism of Donovanosis (Calymmatobacterium granulomatis) in Hep-2 cells. J Clin Microbiol. 35:1997;2915-2917
97. Paterson D.L. Disseminated donovanosis (granuloma inguinale) causing spinal cord compression: case report and review of donovanosis involving bone. Clin Infect Dis. 26:1998;379-383
98. Jardim M.L., Barros E.R., Silveria M. Donovanosis in AIDS patients: description of two cases. An Bras Dermatol Sifilogr. 65:1990;175-177
99. Maniar JK, Desai V. Genital ulcer diseases and HIV status correlation in Bombay, India. Presented at: 8th International Conference on AIDS; July 19-24,1992; Amsterdam, Netherlands
100. Manders S.M., Baxter J.D. Granuloma inguinale and HIV: a unique presentation and novel treatment regimen. J Am Acad Dermatol. 37:1997;494-496
101. Schachter J., Osoba A.O. Lymphogranuloma venereum. Br Med Bull. 39:1983;151-154
102. Schachter J. Chlamydial infections. N Engl J Med. 298:1978;428-435
103. Perine P.L., Stamm W.E. Lymphogranuloma venereum. Holmes K.K., Sparling P.F., Mårdh P.A.,, et al. Sexually transmitted disease. 1999;423-432 McGraw-Hill, New York
104. Engelkens H.J., Stolz E. Genital ulcer disease. Int J Dermatol. 32:1993;169-181
105. Thompson S.E., Washington A.E. Epidemiology of sexually transmitted Chlamydia trachomatisinfections. Epidemiol Rev. 5:1983;96-123
106. Scieux C., Barnes R., Bianchi A., et al. Lymphogranuloma venereum: 27 cases in Paris. J Infect Dis. 160:1989;662-668
107. Kellock D.J., Barlow R., Suvarna S.K., et al. Lymphogranuloma venereum: biopsy, serology, and molecular biology. Genitourin Med. 73:1997;399-401
108. Martin D.H., Mroczkowski T.F. Dermatologic manifestations of sexually transmitted diseases other than HIV. Infect Dis Clin North Am. 8:1994;533-582
109. Mroczkowski T.F., Martin D.H. Genital ulcer disease. Dermatol Clin. 12:1994;753-764
110. Burgoyne R.A. Lymphogranulma venereum. Prim Care. 17:1990;153-157
111. Kraus S.J. Diagnosis and management of acute genital ulcers in sexually active patients. Semin Dermatol. 9:1990;160-166
112. Faro S. Lymphogranuloma venereum, chancroid and lymphogranuloma inguinale. Obstet Gynecol Clin North Am. 16:1989;517-530
113. Mittal A., Sachdeva K.G. Monoclonal antibody for the diagnosis of lymphogranuloma venereum: a preliminary report. Br J Biomed Sci. 50:1993;3-7
114. Bauwens J.E., Orlander H., Gomez M.P., et al. Epidemic lymphogranuloma venereum during epidemics of crack cocaine use and HIV infection in the Bahamas. Sex Transm Dis. 29:2002;253-259
115. Van Dyck E., Piot P. Laboratory techniques in the investigation of chancroid, lymphogranuloma venereum, and donovanosis. Genitourin Med. 68:1992;130-133
116. Allegra F. Lymphogranuloma venereum. Parish L.C., Gschnait F. Sexually transmitted disease: a guide for clinicians. 1989;90-104 Springer-Verlag, New York
117. Treharne J.D., Forsey T., Thomas B.J. Chlamydial serology. Br Med Bull. 39:1983;194-200
118. Aldridge K.E., Cammarata C., Martin D.H. Comparison of the in vitro activities of various parenteral and oral antimicrobial agents against endemic Haemophilus ducreyi. Antimicrob Agents Chemother. 37:1993;1986-1988
119. Stephens R.S., Kuo C.C., Tam M.R. Sensitivity of immunofluorescence with monoclonal antibodies for detection of Chlamydia trachomatis inclusions in cell culture. J Clin Microbiol. 16:1982;4-7
120. Parkash S., Radhakrishna K. Problematic ulcerative lesions in sexually transmitted diseases: surgical management. Sex Transm Dis. 13:1986;127-133